tbuckley/cabot-search huggingface dataset:
Use of the Rapid-Sequence Intravenous Pyelogram in the Diagnosis of Renovascular Hypertension
Authors: Morton H. Maxwell, Harvey C. Gonick, Robert Wiita, Joseph J. Kaufman
Journal: New England Journal of Medicine (1964)

FOR the past several years there has been considerable interest in hypertension secondary to occlusive disease of the renal arteries. This may be ascribed to the development of newer diagnostic technics, particularly arteriography, during a period when there were concomitant rapid advances in the field of reconstructive vascular surgery. Thus, the preferential operative procedure for renovascular hypertension is now considered to be arterial reconstructive surgery, rather than nephrectomy.1 Although as recently as 1956 Smith2 estimated the maximal incidence of surgically treatable renal hypertension to be 2 per cent of all hypertensive patients a more reasonable figure, which is in accord . . .
Dermatologic Complications of Heroin Addiction
Authors: Wilfred Minkin, Harvey J. Cohen
Journal: New England Journal of Medicine (1967)

THE majority of narcotic addicts use heroin (diacetylmorphine). The general medical complications of its use include thrombophlebitis, pulmonary infarction, abscesses, septicemia, bacterial endocarditis, tetanus, malaria1 2 3 4 5 and acute fatal reaction.6 Before the heroin reaches its user it has been "cut" by the addition of adulterants such as lactose, mannitol and quinine so that heroin is only about 18 per cent of the contents of the purchased packet.6 The powder is dissolved in a small amount of boiling water and injected by means of a hypodermic needle attached to either a syringe or a medicine dropper. The preferred route of injection is . . .
Chemopreventive Effect of Grape Juice on NF-Kappa B, Inos and Tnfα in Wistar Rats After Colon Carcinogenesis Induced by Azoximethane
Authors: Vanessa Pazzine, Roseane Silva, Ana Paiotti, Daniel Ribeiro, Nora Forones
Journal: Annals of Oncology (2013)
P690Role of sodium-hydrogen exchange in vascular failure in hereditary cardiomyopathy.
Authors: D Jacques, G Bkaily
Journal: Cardiovascular Research (2014)

Cardiomyopathy in general is defined as a disease of the heart muscle. The purpose of this study is to test the hypothesis that sodium-hydrogen exchanger (NHE1) abnormality is a common cause of cardiac and vascular failures in hereditary cardiomyopathy of the hamster. We verified whether heart failure is accompanied by vascular abnormalities in NHE1.
Abstract 1159: Differential expression of BP1 and associated gene networks in breast cancer of African American women and Caucasian American women
Authors: Thuan H. Nguyen, Patricia E. Berg, Svetlana Ghimbovschi, William E. Grizzle
Journal: Cancer Research (2012)

Abstract Introduction: BP1 is a transcription factor of the homeobox gene family activated in 89% of the tumors of African American women (AAW) compared with 57% of the tumors of Caucasian American women (CAW). AAW with breast cancer have larger tumors and an almost 50% higher mortality rate than CAW. BP1 expression is also associated with larger and more aggressive tumors, suggesting BP1 may contribute to the aggressiveness of tumors of AAW. Importantly, BP1 appears to be involved in the epithelial to mesenchymal transition (EMT), based on (i) activation of Twist, a trigger of EMT, (ii) decreased expression of epithelial markers, and (iii) increased expression of mesenchymal markers in cells engineered to overexpress BP1; EMT can lead to metastasis. Here we set out to identify molecular pathways underlying the discrepancy of breast cancer aggressiveness in AAW and CAW with particular attention to BP1 regulated pathways. Results: Cell line analysis. We analyzed five cell lines derived from tumors of AAW and five derived from CAW for EMT markers, including E-CADHERIN (epithelial) and VIMENTIN (mesenchymal). Interestingly, in both types of cell lines, two were epithelial, one was mesenchymal, and two were not classifiable. Two of the AAW derived cell lines and three of the CAW derived cell lines were further studied using microarrays. Preliminary analysis revealed that MYC, CASPASE3, and PPARG are overly represented in the cell lines derived from AAW compared to their CAW derived counterparts; these cell lines also overexpress BP1. Further studies will be performed to determine other pathways that may be differentially expressed in the cell lines from AAW and to determine whether BP1 regulates those pathways. Clinical studies. Tumor tissues from AAW and CAW, matched for age and stage of breast cancer, will be immunostained to determine differential expression of BP1 and EMT markers, and genes identified by microarray analysis as being regulated by BP1. Localization studies of BP1 protein revealed that the nuclear membrane stained most intensely for BP1, with nucleus &amp;gt; cellular membrane &amp;gt; cytoplasm staining. Nuclear and cytoplasmic staining for BP1 tended to be less for CAW than AAW. Conclusions: Our data identify several molecular pathways that may be preferentially activated in breast cancer of AAW. Genes that are overexpressed in tumors of AAW compared with tumors of CAW would make good targets for therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1159. doi:1538-7445.AM2012-1159
Abstract 429: The value of Tenascin-C expression in neoadjuvant breast cancer therapy
Authors: Stephan Bastelberger, Stefan Swierczynski, Leon Pradel, Jane Beil, Elisabeth Hinterseer, Gundula Rendl, Cornelia Hauser-Kronberger, Otto Dietze
Journal: Cancer Research (2011)

Abstract Introduction: The extra cellular matrix molecule Tenascin-C (TNC) in its many isoforms is highly expressed during tissue repair and pathological conditions such as cancer and stress. Utilising the selective pressure of neoadjuvant chemotherapy on carcinoma cells we screened for a subgroup of breast cancer patients with elevated TNC expression and a bad therapy response. TNC expression was correlated with biomarkers, histopathological (stage) and clinical data. Breast cancer cell lines were tested on TNC levels and their expression behaviour under competitive conditions. Methods: Paraffin sections from 68 preoperatively treated breast cancer patients were used for automated immunohistochemistry (IHC) with antibodies targeting TNC, AE1/AE3, Ki67, CD3 and p53. In addition F-18 FDG PET-CT was performed to evaluate therapy response. Protein- and gene expression experiments performed onto six breast cancer cell lines (MCF-7, MDA-MB231, MDA-MB453, SK-BR3, SUM-159, T47-D) showed TNC-expression in MDA-MB453 breast cancer cell line. Gene expression of TNC in hedgehog positive cells (MCF-7) was evaluated after co-cultivation with TNC positive cells (MDA-MB453) by qRT-PCR. The qRT-PCR results confirmed the protein expression results on in vitro stained cell-slides after cell-cell interactions and different growth times. Growth and migration behaviour was studied in 3D-matrigels. Results: We demonstrate that TNC expression in breast cancer is immensely reduced after neoadjuvant chemotherapy (43% of patients lost TNC expression) and that expression profiles after treatment correlate with tumor grade, lymph node status and estrogen receptor status, indicating prognostic value, probably for endocrine treatment. Post-therapeutical correlation and co-localisation of the proliferation marker Ki67 in cancer cells and TNC in the surrounding tumor-stroma of patients having a less beneficial response to chemotherapy. The evaluation of expression levels revealed a linear correlation of TNC and Ki67. Submitting cell lines to selective environmental pressure on cell chamber slides, we observed differentiated staining patterns and cellular localization for TNC. After co-cultivation with MDA-MB453, the hedgehog positive cell line MCF-7 expressed highly elevated levels of TNC. Conclusions: These findings concur with the role of TNC in tissue reorganisation, wound healing and it's growth promoting properties in cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 429. doi:10.1158/1538-7445.AM2011-429
Screening of Selected Male Blood Donors for p24 Antigen of Human Immunodeficiency Virus Type 1
Authors: M P Busch, P E Taylor, B A Lenes, S H Kleinman, M Stuart, C E Stevens, P A Tomasulo, J P Allain, C G Hollingsworth, J W Mosley
Journal: New England Journal of Medicine (1990)

The p24 antigen of human immunodeficiency virus type 1 (HIV-1) is sometimes detected before antibody (anti-HIV-1) is detectable in the serum of recently infected persons. This has led to the consideration of p24-antigen testing for routine screening of blood donors.
The Early Treatment of Pulmonary Tuberculosis
Authors: Carl W. Tempel, Dumont Clark
Journal: New England Journal of Medicine (1952)

THE therapy of pulmonary tuberculosis has progressed markedly in recent years. It is desirable, therefore, to review present trends in treatment for the benefit of those not actively engaged in tuberculosis research and in the hospital care of patients. A final pattern of treatment has not yet emerged, but enough has been accomplished so that the physician can offer the patient with newly discovered1 pulmonary tuberculosis a fairly specific course of therapy for his disease. To this end it is proposed to indicate briefly the place of rest in the treatment of pulmonary tuberculosis; to discuss certain developments in therapy . . .
LEFT VENTRICULAR OUTCOMES FOLLOWING MULTIVESSEL PCI VERSUS INFARCT-ONLY PCI IN PATIENTS WITH ACUTE STEMI: THE GLASGOW PRAMI CMR SUB-STUDY
Authors: Kenneth Mangion, David Carrick, Alexander R. Payne, John McClure, Maureen Mason, Mark Petrie, Margaret McEntegart, Hany Eteiba, Keith Oldroyd, Colin Berry
Journal: Journal of the American College of Cardiology (2015)
SAT0399 The Patient-Derived PSA Impact of Disease (PSAID) Questionnaire Correlates with Other Outcome Measures: HÜR-BİO REAL Life Results
Authors: L. Kilic, O. Karadag, L. Gossec, S. Apras Bilgen, A. Akdogan, S. Kiraz, I. Ertenli, U. Kalyoncu
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Recently, a EULAR (European League Against Rheumatism) working group developed the PsA impact of disease (PsAID) questionnaire which is a patient-derived composite index which assesses pain, skin problems, fatigue, work and/or leisure activities, functional capacity, uncomfortable feelings, sleep problems, anxiety-fear and uncertainty, coping, distress and/or embarrassment, social participation, and depression<sup>1</sup>. However this questionnaire has not yet been validated in other cohorts. <h3>Objectives</h3> To validate the PsAID questionnaire in terms of correlation to other outcome measures in routine practice. <h3>Methods</h3> Between January-December 2013, PsA patients on anti-TNF treatment were included in the HURBIO (Hacettepe University Rheumatology Biologic Registry) pragmatic observational study. Data collection comprised PsAID, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Dermatology Life Quality Index (DLQI), Health Assessment Questionnaire (HAQ), patient global Visual Analogue Scale (VAS), tender/swollen joints counts and DAS28. Non-parametric correlations between the PSAID score and the other outcome measures were assessed cross-sectionally. Feasibility was assessed by % missing data. <h3>Results</h3> 111 patients were assessed: females 70%, mean age 44±12 years, mean disease duration 10.3±7,6 years, median anti-TNF treatment duration 16 (0- 100) months. There was a good correlation between PsAID and BASDAI (r=0.71), BASFI (r=0.72), HAQ (r=0.60), DLQI (r=0.47), and patient global VAS (r=0.59), and as expected correlations were moderate versus DAS28CRP (r=0.55), swollen joint count (r=0.25), and tender joint count (r=0.39). There was no correlation vs ESR or CRP level. Missing data in the 12 questions of the PsAID was unfrequent: 0.5%. <h3>Conclusions</h3> PsAID is a recently developed patient reported outcome measure for PsA. In this study we showed that PsAID correlates with other composite indices for patients with PsA treated by anti-TNF. Furthermore the PsAID questionnaire was easy to fill in for the patient indicating good acceptability in a non-Western culture. <h3>References</h3> Gossec, Laure, de Wit, Maarten, Balanescu, Andra, Balint, Peter V., Bekes, Gabor, Braun, Juergen, et al; Patient-Perceived Impact of Psoriatic Arthritis Is Due to Pain and Fatigue, but Also to Psychological Aspects – the Psa Impact of Disease Study. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1296 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3915
Abstract 3611: LY2801653, an orally available small molecule inhibitor of c-Met, demonstrated broad antitumor efficacy in patient derived xenograft models
Authors: Wei J. Yang, Kelly Credille, Hong Gao, Mark Uhlik, Julie Pomeroy, Richard Walgren, Chuan Shih, Steffen Baltes, Thomas Beckers, Jonathan M. Yingling
Journal: Cancer Research (2010)

Abstract The receptor tyrosine kinase c-Met and its ligand hepatocyte growth factor (HGF) play important roles in cell growth, migration, and survival. Dysregulation of the c-Met/HGF signaling pathway has been found in many human malignancies. LY2801653 was identified and developed as a novel, potent, and orally active small molecule inhibitor of human c-Met. It demonstrated dose dependent inhibition of c-Met phosphorylation in xenograft tumors with a long lasting PD effect. In the current study, the anti-tumor activity of LY2801653 was evaluated in a panel of human patient derived xenograft models. LY2801653 displayed potent anti-tumor efficacy in a number of non small cell lung, renal, pancreatic, and breast tumor models. Examination of c-Met expression in these tumors by immunohistochemistry (IHC) revealed a good correlation between response and c-Met expression in the tumor tissue. Interestingly, the two non small cell lung adenocarcinoma models LXFA526 and LXFA1647 that were resistant to EGFR inhibitors Cetuximab and Erlotinib, displayed high sensitivity towards LY2801653. High level of genomic amplification of c-Met locus was found in these models, consistent with the hypothesis that c-Met activation represents one of the resistant mechanisms to EGFR inhibition. LY2801653 treatment led to increase in functional vessel areas, and decrease in tumor hypoxia. Enhanced anti-tumor efficacy was achieved when Erlotinib was combined with LY2801653. In summary, these results demonstrated the promising therapeutic potential of LY2801653 in mono and combination therapy of cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3611.
PWE-086 Polyp size measurements in the bowel cancer screening programme
Authors: J Turner, M Wright, M Morgan, G Williams, S Dolwani
Journal: Gut (2012)

Introduction Polyp size is a principal factor used to determine surveillance intervals both nationally and internationally, and is an independent risk factor for the malignant potential of colorectal lesions. There is uncertainty regarding the most accurate method of measurement of colonic polyps, between the in situ and post-formalin fixation measurements. This study aims to determine the preferred polyp measurement for use in determining surveillance intervals and compare post-fixation polyp measurements using three different devices. Methods 107 consecutive colorectal polyps were measured in situ, pre-fixation and post-fixation to the nearest millimetre. Post-fixation measurements were recorded using a metal ruler, callipers and a graduated magnifying lens. One sample t-tests and the Kruskall–Wallis test were used for data analysis. Results Pre-fixation ruler measurements were significantly higher than both in situ and post-fixation ruler measurements (p<0.05). However no significant difference was observed between in situ and post-fixation measurements (p=0.36). In situ measurements were associated with a higher rate of surveillance group variation than post-fixation measurements (9.3% vs 5.6%). No significant difference was seen between measurements obtained by the three different devices post-fixation (p=0.89). Conclusion Post-fixation polyp size measurements are associated with lower rates of surveillance variation and may be considered the preferred measurement. On average colonoscopists underestimated polyp size. In the absence of a clinically significant difference between measurement devices, we advise the ruler be used for post-fixation measurements due to its widespread availability. Competing interests None declared.
Diffuse Elevated MIBG Activity in the Renal Parenchyma Caused by Compromised Renal Blood Flow
Authors: Bin Liu, Ion Codreanu, Jigang Yang, Sabah Servaes, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2014)

Increased metaiodobenzylguanidine (MIBG) activity in the kidneys is usually focal and commonly attributed to radioactive urine accumulation in the renal pelvis. Hereby, we present 2 cases of abnormal diffuse MIBG activity in the kidneys caused by compromised renal blood flow. The patterns should be differentiated from physiologic renal MIBG activity, especially when the uptake is relatively symmetric as well as from regional MIBG-avid disease.
P806 PREVALENCE AND DETERMINANTS OF FATTY LIVER IN NORMAL WEIGHT AND OVERWEIGHT YOUNG ADULTS. THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY
Authors: E. Suomela, M. Oikonen, J. Virtanen, R. Parkkola, E. Jokinen, T. Laitinen, N. Hutri-Kähönen, M. Kähönen, T. Lehtimäki, L. Taittonen, P. Tossavainen, A. Jula, B.-M. Loo, Z. Younossi, J. Viikari, M. Juonala, O.T. Raitakari
Journal: Journal of Hepatology (2014)
P24 * A RETROSPECTIVE ANALYSIS OF THE TRANSFORMATION OF LOW-GRADE GLIOMAS INTO HIGH-GRADE FROM A SINGLE INSTITUTION
Authors: A. Leggate, T. Ioannou, T. Eadsforth, J. Law, G. Hall
Journal: Neuro-Oncology (2014)

INTRODUCTION: The management and timing of treatment for Low Grade Gliomas (LGG) has been a controversial topic in neuro-oncology for several years. The main aim of this report is to identify what proportion of and the time frame during which LGG will undergo malignant transformation into High-Grade Gliomas (HGG). METHOD: A retrospective analysis of a total of 86 patients from a single institution was conducted. The individual patient medical records were reviewed for date of initial diagnosis and date of recurrence as well as the initial and subsequent disease management. RESULTS: The median age at diagnosis was 41 years (IQR 29 to 51) and the male to female ratio was 47:39. Initial presenting symptoms included epilepsy (65.1%), headache (38.4%), and neurological deficit (14.0%) whereas six cases were identified incidentally. Around half (48.84%) of the patients experienced progression of the disease and required further management with the median time to progression (TTP) being 4.14 years (95% CI, 2.78 to 5.50), whereas the median follow-up time period for the entire population sample was 3.94 years (95% CI, 3.53 to 4.35 years). Univariate analysis revealed that none of the prognostic factors including age at diagnosis, tumour location and histology, gender and surgical approach reached statistical significance. Finally multivariate analysis by means of the Cox proportional hazard model identified statistically significant differences associated with gender and age at diagnosis. CONCLUSION: This study revealed that almost half of the patients diagnosed with LGG will progress to HGG and that the majority of them will do so in the first five years following the diagnosis.
AB1135 Arthropathy of down syndrome: From child to adult. Case report
Authors: E. Koskova, E. Vrtikova, Z. Pechociakova
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Down syndrome (DS), the result of trisomy of chromosome 21 causing mental retardation, various structural abnormalities or disturbance of organ systems, is one of the most common chromosomal abnormalities. Orthopedic manifestations occur frequently in DS, most of them are related to hypotonia, joint hypermobility and ligamentous laxity (1). DS is predisposing to various autoimmune diseases, such as diabetes, thyroid disease and celiac disease. Prevalence of DS arthropathy in general population is more than 6 times higher than that of juvenile idiopathic arthritis (JIA) (2). <h3>Objectives</h3> A 22-year old female with DS had since 11 years of age history of pain of her wrists, fingers, ankles and toes, and of morning stiffness for 1-2 hours. At the age of 13, we have diagnosed her with juvenile idiopathic RF-negative polyarthritis. Family history of arthritis was negative. Physical examination revealed limited range of motion and swelling in her elbows, wrists and ankles, as well as in bilateral metacarpophalangeal (MCP), proximal and distal interphalangeal (PIP) joints. Laboratory results showed a negative ANA, RF, ESR 32/hour, CRP 19.8 mg/dl and increased IgG (20.7 g/l). Hand X-Ray showed diffuse soft tissue swelling in her left wrist and PIP joints, bilateral MCP1 subluxation, and subluxation with space narrowing of left wrist. Foot X-Ray indicated periarticular osteoporosis, bilateral hallux valgus, right metatarsophalangeal joint (MTP5) erosion. Ankle X-Ray showed narrowing of the right talocrural space and diffuse bilateral soft tissue swelling. Treatment with methotrexate, naproxen and low dose prednisone resulted in improvement of clinical symptoms and stable conditions for several years. Nine years later our patient has irreversible joint damage and functional limitation without elevated inflammatory markers and active arthritis. X-Ray of hands showed worsening: usuration of left radiocarpal joint, erosions in left MCP 2,3 and 4, left wrist collapse, and right wrist deaxation. X-Ray of cervical spine revealed atlantoaxial subluxation of 5 mm without clinical symptoms. Patient continues with methotrexate therapy and daily physical therapy at home. Despite functional and radiographic worsening the patient and her parents are content with her condition. <h3>Conclusions</h3> Therapy with MTX was clinically effective, but did not prevent progression of arthropathy and disability in our patient. Prolonged methotrexate therapy in our patient is well tolerated and safe. Atlantoaxial subluxation is common in patient with JIA and DS. <h3>References</h3> Yancey, C.L., Zmijewski, Ch, Arthreya, B.H., Doughty, R.A: Arthropathy of Down's syndrome. Arthritis Rheum 1984, 27: 929- 934 Juj, H., Emery, H.: The Arthropathy of Down syndrome: An Underdiagnosed and Under- recognized Condition. J.Pediatr. 2009, 154: 234-8 <h3>Disclosure of Interest</h3> None Declared
Post-Tachycardia T-Wave Syndrome
Authors: A M Katz
Journal: New England Journal of Medicine (1995)

Figure 1. Serial electrocardiograms (lead V4) were obtained in a 67-year-old man taking digoxin for paroxysmal supraventricular tachycardia. An electrocardiogram obtained on June 28, 1983, showed no abnormalities. About six weeks later on August 15, while awaiting surgery for peripheral vascular disease, the patient had an episode of paroxysmal supraventricular tachycardia (first electrocardiogram in second row) that responded to carotid-sinus massage. An electrocardiogram obtained shortly after conversion to sinus rhythm showed atrial premature beats and minor T-wave inversions (second electrocardiogram in second row), which became deeper over the next 24 hours (third electrocardiogram in second row). The patient . . .